AP Biosciences Doses First Patient in Phase 1/2 Trials for HER2+ Cancer

AstraZeneca and Daiichi Sankyo's drug Enhertu demonstrated a highly statistically significant improvement in progression-free survival and survivability rates for patients with metastatic HER2-positive breast cancer in a late-stage global clinical trial. The results, which compared Enhertu (alone and combined with pertuzumab) to the current standard three-drug regimen, mark the first time in over a decade that a new therapy has proven more effective for a broad range of these patients. This advancement is considered especially important as many with metastatic breast cancer do not reach a second line of treatment. The positive trial outcomes are seen as a potential boost for AstraZeneca's future revenue and growth prospects, even as its share price recently declined amid broader market pressures. Enhertu, first approved in 2019, has expanded its indications and may now see broader first-line use thanks to these findings.